Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
Socié, Gérard (Hôpital Saint-Louis)
Barba, Pere (Hospital Universitari Vall d'Hebron)
Barlev, Arie (Atara Biotherapeutics)
Sanz, Jaime (Hospital Universitari i Politècnic La Fe de València)
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau)
Chevallier, Patrice (University Hospital of Nantes)
Fagioli, Franca (University of Turin)
Guzman-Becerra, Norma (Atara Biotherapeutics)
Kumar, Deepali (University Health Network)
Ljungman, Per (Karolinska University Hospital)
Pigneux, Arnaud (Centre Hospitalier Universitaire de Bordeaux)
Sadetsky, Natalia (Atara Biotherapeutics)
Yáñez San Segundo, Lucrecia (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantabria))
Shadman, Mazyar (Fred Hutchinson Cancer Center)
Storek, Jan (University of Calgary)
Thirumalai, Dhanalakshmi (Atara Biotherapeutics)
Xing, Baodong (Atara Biotherapeutics)
Mohty, Mohamad (Sorbonne University)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	Epstein-Barr virus-positive (EBV +) post-transplant lymphoproliferative disease (PTLD) is an ultra-rare and aggressive condition that may occur following allogeneic hematopoietic cell transplant (HCT) due to immunosuppression. Approximately half of EBV + PTLD cases are relapsed or refractory (R/R) to initial rituximab-containing therapy. There are limited treatment options and no standard of care for patients with R/R EBV + PTLD, and little is known about their treatment history and outcomes. We performed a multinational, multicenter, retrospective chart review of patients with R/R EBV + PTLD following HCT to describe patients' demographic and disease characteristics, treatment history, and overall survival (OS) from rituximab failure. Among 81 patients who received initial treatment with rituximab as monotherapy (84. 0%) or in combination with chemotherapy (16. 0%), median time from HCT to PTLD diagnosis was 3. 0 months and median OS was 0. 7 months. Thirty-six patients received a subsequent line of treatment. The most frequent causes of death were PTLD (56. 8%), graft-versus-host disease (13. 5%) and treatment-related mortality (10. 8%). In multivariate analysis, early PTLD onset and lack of response to initial treatment were associated with mortality. This real-world study demonstrates that the prognosis of patients with R/R EBV + PTLD following HCT remains poor, highlighting the urgent unmet medical need in this population.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Haematological cancer
Publicat a:	Bone marrow transplantation, Vol. 59 (october 2023) , p. 52-58, ISSN 1476-5365

DOI: 10.1038/s41409-023-02127-9
PMID: 37865719

7 p, 730.8 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats